Related Experiment Video
Updated: Oct 10, 2025

The Treadmill Fatigue Test: A Simple, High-throughput Assay of Fatigue-like Behavior for the Mouse
Published on: May 31, 2016
Association between fatigue and sleep disturbances during treatment for pediatric acute lymphoblastic leukemia and
Priscilla Vasquez1, Johanna Escalante2, Kimberly P Raghubar2
1Department of Pediatrics, Section of Oncology, Baylor College of Medicine, Houston, Texas, USA.
Insights
High fatigue and sleep disturbances during acute lymphoblastic leukemia (ALL) treatment in children are linked to poorer long-term neurocognitive outcomes, particularly attention deficits.
Area of Science:
- Pediatric Oncology
- Neuroscience
- Sleep Medicine
Background:
- Survivors of pediatric acute lymphoblastic leukemia (ALL) face increased risks of neurocognitive deficits, including issues with attention, executive function, and processing speed.
- While fatigue and sleep disturbances are common during ALL treatment and affect cognition, their long-term impact on neurocognitive performance post-treatment is not well understood.
Purpose of the Study:
- To investigate the relationship between fatigue and sleep profiles during active pediatric acute lymphoblastic leukemia (ALL) treatment and subsequent neurocognitive performance.
- To identify distinct subgroups of patients based on their fatigue and sleep patterns during therapy.
Main Methods:
- A cohort of 120 pediatric patients with ALL completed fatigue and sleep questionnaires at four time points during treatment.
- Latent class growth analysis identified patient subgroups with similar fatigue and sleep trajectories.
- Neurocognitive performance was assessed in 40 participants more than six months after treatment completion and compared between identified subgroups.
Main Results:
- Two distinct fatigue and sleep profiles were identified: Class 1 (mild disturbances) and Class 2 (higher disturbances), representing 50.8% and 49.2% of patients, respectively.
- Most post-treatment cognitive measures were within the normal range, but attention, executive function, and verbal short-term memory were below normative means.
- Patients in Class 2 exhibited significantly poorer neurocognitive performance compared to Class 1, especially in attention-related tasks.
Conclusions:
- Fatigue and sleep disturbances experienced during the initial year of pediatric ALL therapy may negatively influence long-term neurocognitive functioning.
- Targeting interventions for sleep and fatigue during treatment could be crucial for preserving cognitive abilities in pediatric ALL survivors.
Background:
Survivors of pediatric acute lymphoblastic leukemia (ALL) are at increased risk of neurocognitive weakness in the areas of attention, executive function, and processing speed. Although fatigue and sleep disturbances are frequent complications of ALL therapy and associated with cognitive functions, the impact of fatigue and sleep profiles during active ALL treatment on posttreatment neurocognitive performance has received limited attention.
Methods:
Pediatric patients (n = 120) with ALL (diagnosed 2011-2016) who completed fatigue and sleep questionnaires at four time points during active treatment were enrolled in a study of neurocognitive performance. Latent class growth analysis identified subgroups of patients with similar sleep and fatigue profiles during treatment. Neurocognitive performance collected >6 months post treatment on 40 participants was compared between latent classes using multivariable linear regression models.
Results:
Participants (57.5% male and 79.1% Hispanic or non-Hispanic White) were classified into one of two fatigue and sleep profiles: Class 1 characterized by mild fatigue and sleep disturbances during treatment (50.8%), and Class 2 characterized by higher levels of fatigue and sleep disturbances (49.2%). Posttreatment cognitive performance was in the normal range for most measures, but significantly below normative means for executive function, verbal short-term memory, attention, and distractability measures. Compared to Class 1, Class 2 demonstrated significantly (p < .05) poorer posttreatment neurocognitive performance, particularly in measures of attention.
Conclusions:
Our findings indicate that fatigue and sleep disturbances during the first year of pediatric ALL therapy may impact long-term neurocognitive performance. Sleep and fatigue may be targets for intervention to preserve cognitive functioning in survivors.
More Related Videos
Related Concept Videos
Substance Use Disorders Affecting Sleep
Understanding the concepts of physical dependence,...
Fatigue
Insufficient Sleep and Sleep Deprivation
Sleep deprivation is a more severe form of sleep loss...

